While CCND1 displayed high copy number versus expression correlations in liver cancer (r = 1.0), bladder cancer (r = 0.8), lung squamous cancer (r = 0.7), head and neck caner (r = 0.7) and breast cancer (r = 0.7), the correlations were lower in other cancer types, suggesting that CCND1 amplification is a disease-specific oncogenic driver (Figure 3). This evidence concerns the gene CCND1 and urinary bladder carcinoma.